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Sirs,
Recombinant human erythropoietin was introduced in 1988
for the treatment of anemia in chronic kidney disease
(CKD). The development of antibodies against epoetin was
ararecomplicationduringthefirstdecadeofitsuse.However,
in 1998 there was a sudden increase in epoetin-induced
antibodies associated with pure red cell aplasia (PRCA) in
patientswithCKDwhohadbeenusingEprex,asubcutaneous
epoetin-alfa product marketed in Europe [1, 2]. Although the
recombinant epoetin products differ in glycosylation, the
increase in PRCA was probably caused by a change in
the formulation of Eprex in which human serum albumin
was replaced by glycine and polysorbate 80 [3]. Switching
patients from subcutaneous to intravenous administration
and adding Teflon to the rubber stopper of prefilled Eprex
syringes subsequently eliminated nearly all antibody forma-
tion. For epoetin-beta, antibody-associated PRCA is even
rarer, as evidence by the very few cases that have been
published. We present here the first report of a child who
developed antibody-associated PRCA elicited by the use of
epoetin-beta.
The patient was born on the Dutch Antilles. In 2004,
at the age of 5 years, he developed renal failure due to
persistent obstructive uropathy. His CKD-related anemia
was treated with epoetin-beta subcutaneously from 2004
onwards (2×2000 IE/week). After 1.5 year of use, he
developed a progressive transfusion-dependent anemia
unresponsive to recombinant epoetin-beta (Neorecormon:
maximum 5×2000 IE/week) and presented at our
hospital (Fig. 1). An increase in the epoetin-beta dose
to 5×6000 IE/week had no effect on the reticulocyte
count, demonstrating that the anemia was unresponsive to
epoetin-beta.
Laboratory testing revealed the following: hemoglobin
(Hb), 2.8 mmol/L; reticulocyt count, <0.1%; MCV, 83;
white blood cells (WBC), 11.7×10
9/L; platelet count,
228×10
9/L. There were no signs of hemolysis: lactate
dehydrogenase, 184 U/L; haptoglobin, 0.99 g/L. The
combination of anemia, low reticulocyte count, and normal
leukocyte and trombocyte count with the use of epoetin-
beta suggested a diagnosis of antibody-mediated PRCA.
Anti-epoetin immunoglobulin (Ig) G antibodies identified
by means of an antigen binding assay, essentially as
described by Aalberse et al. [4], were indeed elevated.
Treatment was initiated with one pulse methylprednisolone
(15 mg/kg), followed by prednisone 1 mg/kg/day, and
cyclosporine 4 mg/kg/day (trough levels 50–100 mg/l).
Within days of starting this treatment, anti-epoetin-
antibodies levels declined and were undetectable after
2 months of treatment (Fig. 1). The reticulocyte count
increased to 2% after 3 months, and from then on Hb
remained at acceptable levels between 5 and 7 mmol/L
without the need for blood transfusions (Fig. 1). After 3
months, the prednisone dosage was reduced to 7.5 mg
(0.3 mg/kg/day) and the cyclosporine dosage to 3 mg/kg/day
until transplantation. One year later a successful family
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6.5 mmol/L 4 months after transplantation (Fig. 1).
This 5-year-old boy developed PRCA caused by anti-
epoetin-antibodies following exclusive treatment with
epoetin-beta subcutaneously.Thesubcutaneousadministration
of epoetin may have rendered the immune system of this boy
more susceptible to antibody formation.
Treatment options for antibody-associated PRCA are
invariably based on case reports or case-series. Several
immunosuppressive drugs have been tried: corticosteroids
alone, cyclophosphamide, cyclosporine, mycophenolate
mofetil, intravenous immunoglobulin, and anti-CD20
monoclonal antibodies, with or without corticosteroid
treatment. Although the results of different strategies vary,
all patients who had a kidney transplant showed a full
recovery of erythropoiesis [5]. Our patient responded well
to a pulse of methylprednisolone followed by prednisone
and low-dose cyclosporine. After this treatment the Hb
remained stable, indicating the permanent disappearance of
antibodies. No side-effects of our treatment were noted, and
a successful renal transplantation was ultimately performed.
In conclusion, the combination of prednisone and
cyclosporine in a low dose was successful in the treatment
of anti-epoetin-antibody-induced anemia in a child with
chronic renal failure.
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Fig. 1 Treatment regimen of progressive transfusion-dependent
anemia unresponsive to recombinant epoetin-beta in our young patient
with chronic kidney failure. Hb hemoglobin
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